At a glance
ClinicalIndex Comparison RecordN/ACompleted· 750 target
Drug / intervention
Piribedildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.
In Brief
An observational study evaluating Piribedil for Parkinson's Disease. Completed, enrolled 750 participants across 2 sites.
Detailed Summary
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedAug 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedAug 4, 2008
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.9 years ago
Interventions
Piribedildrug